KalVista Pharmaceuticals - KALV Stock Forecast, Price & News

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for KalVista Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" KALV shares.
View KALV analyst ratings or view top-rated stocks.

3 Wall Street analysts have issued 12 month price targets for KalVista Pharmaceuticals' stock. Their KALV share price forecasts range from $16.00 to $22.00. On average, they anticipate the company's share price to reach $19.33 in the next twelve months. This suggests a possible upside of 159.5% from the stock's current price.
View analysts price targets for KALV or view top-rated stocks among Wall Street analysts.

KalVista Pharmaceuticals' stock was trading at $6.76 at the beginning of 2023. Since then, KALV shares have increased by 10.2% and is now trading at $7.45.
View the best growth stocks for 2023 here.

KalVista Pharmaceuticals saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 2,460,000 shares, an increase of 13.4% from the February 28th total of 2,170,000 shares. Based on an average daily volume of 351,700 shares, the short-interest ratio is presently 7.0 days.
View KalVista Pharmaceuticals' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, July 6th 2023.
View our KALV earnings forecast.

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) posted its quarterly earnings results on Thursday, December, 9th. The specialty pharmaceutical company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.79) by $0.01.

Invesco Nasdaq Future Gen 200 ETF holds 4,669 shares of KALV stock, representing 0.71% of its portfolio.

Based on aggregate information from My MarketBeat watchlists, some companies that other KalVista Pharmaceuticals investors own include Heron Therapeutics (HRTX), Sorrento Therapeutics (SRNE), Cara Therapeutics (CARA), SCYNEXIS (SCYX), TG Therapeutics (TGTX), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Catalyst Pharmaceuticals (CPRX), Corbus Pharmaceuticals (CRBP) and Pfizer (PFE).

KalVista Pharmaceuticals trades on the NASDAQ under the ticker symbol "KALV."

KalVista Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Frazier Life Sciences Management L.P. (13.16%), Tang Capital Management LLC (12.98%), VR Adviser LLC (11.85%), Jefferies Financial Group Inc. (4.87%), Driehaus Capital Management LLC (4.11%) and Opaleye Management Inc. (3.75%). Insiders that own company stock include Albert Cha, Andreas Maetzel, Benjamin L Palleiko, Christopher Yea, Edward P Feener, Miami Jewish Federatio Greater, Michael David Smith, Paul K Audhya and Thomas Andrew Crockett.
View institutional ownership trends.

Shares of KALV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of KALV stock can currently be purchased for approximately $7.45.

KalVista Pharmaceuticals (NASDAQ:KALV) has a market capitalization of $254.57 million and generates $12.69 million in revenue each year. The specialty pharmaceutical company earns $-82,340,000.00 in net income (profit) each year or ($3.57) on an earnings per share basis.

KalVista Pharmaceuticals' mailing address is 55 Cambridge Parkway Suite 901E, CAMBRIDGE MA, 02142. The official website for the company is www.kalvista.com. The specialty pharmaceutical company can be reached via phone at 857-999-0075, via email at ir@kalvista.com, or via fax at 866-553-3269.